The seven major inflammatory bowel disease markets will grow by more than 60% to $5.6 billion in 2019 finds a new report from independent market analyst Datamonitor.
Datamonitor believes growth will be driven by the launch of seven pipeline drugs for Crohn's disease, ulcerative colitis, or both indications; some with new mechanism of action.
James Wentworth, senior healthcare analyst at Datamonitor comments: 'New drug launches, combined with the impending impact from the seminal SONIC study and an increased use of biologics in ulcerative colitis will drive sales growth over the next ten years in the seven major markets.
'Whilst we forecast strong growth, equivalent to a combined annual growth rate (CAGR) of 4.7%, it is worth noting that this is a slowdown compared to previous years. Inflammatory bowel disease sales grew steeply in the seven major markets between 2006 and 2009, at a CAGR of 24%. This was due to a combination of uptake of drugs, such as Abbott's Humira (adalimumab), price increases and the earlier treatment of patients with expensive biologics, particularly in those who have fistulizing disease and bad prognostic features of disease."
Despite predicted growth, Datamonitor does warn that drug costs will influence the future of the market.
'Crohn's disease is a lifelong disease and the increasing use of biologics coupled with rising costs of therapies will put significant pressure on market payers. Long-term cost reductions may become necessary", concludes James
A Pain In The Gut